Superluminal Medicines Secures $120 Million Series A Funding
Summary
New investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP joined in the financing, and Diamantis Xylas, MD of Catalio joined the Board of Directors.The funds will support the progression of Superluminal Mediciness lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets. Superluminals platform and team have demonstrated success, and we are pleased to continue to support the companys further growth and development.Superluminals focus is on membrane receptors that mediate cell signaling and response processes fundamental to human physiology and constitute major classes of drug targetsincluding GPCRs, ion channels, and transporters. By understanding and leveraging these dynamic properties, we can intervene positively within the natural context of the cell and the body.The companys board of directors offers a wealth of industry expertise to guide Superluminal. The companys platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect.Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.